Pfizer (PFE) Stock Rating Reaffirmed by Barclays

Pfizer (NYSE:PFE)‘s stock had its “neutral” rating reissued by equities researchers at Barclays in a report issued on Wednesday. They currently have a $40.00 price objective on the biopharmaceutical company’s stock. Barclays’ price objective suggests a potential downside of 9.09% from the stock’s previous close.

PFE has been the subject of several other reports. Goldman Sachs Group reiterated a “neutral” rating and set a $45.00 target price on shares of Pfizer in a report on Tuesday, August 28th. Cantor Fitzgerald initiated coverage on shares of Pfizer in a report on Thursday, June 7th. They issued an “overweight” rating and a $45.00 price objective for the company. Credit Suisse Group boosted their price objective on shares of Pfizer from $39.00 to $40.00 and gave the stock a “neutral” rating in a report on Wednesday, August 1st. Morgan Stanley set a $45.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a report on Thursday, September 6th. Finally, JPMorgan Chase & Co. set a $42.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a report on Monday, September 10th. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have assigned a buy rating to the company. Pfizer has a consensus rating of “Hold” and a consensus price target of $41.89.

Shares of PFE stock traded up $0.32 during trading hours on Wednesday, hitting $44.00. 288,649 shares of the company’s stock traded hands, compared to its average volume of 17,725,164. Pfizer has a 12-month low of $33.20 and a 12-month high of $44.46. The firm has a market capitalization of $260.68 billion, a price-to-earnings ratio of 16.54, a PEG ratio of 2.21 and a beta of 0.96. The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.91 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, July 31st. The biopharmaceutical company reported $0.81 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.74 by $0.07. Pfizer had a net margin of 42.35% and a return on equity of 25.35%. The firm had revenue of $13.47 billion during the quarter, compared to analyst estimates of $13.30 billion. During the same period last year, the business earned $0.67 earnings per share. The business’s revenue was up 4.4% on a year-over-year basis. sell-side analysts forecast that Pfizer will post 2.99 earnings per share for the current fiscal year.

In other Pfizer news, VP Loretta V. Cangialosi sold 26,814 shares of Pfizer stock in a transaction that occurred on Wednesday, August 1st. The shares were sold at an average price of $40.16, for a total value of $1,076,850.24. Following the completion of the sale, the vice president now owns 102,360 shares of the company’s stock, valued at approximately $4,110,777.60. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Ian C. Read sold 486,753 shares of Pfizer stock in a transaction that occurred on Monday, July 16th. The stock was sold at an average price of $37.36, for a total transaction of $18,185,092.08. Following the completion of the sale, the chief executive officer now directly owns 1,145,693 shares of the company’s stock, valued at approximately $42,803,090.48. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 761,230 shares of company stock valued at $29,054,690. 0.06% of the stock is owned by company insiders.

A number of large investors have recently bought and sold shares of PFE. Ballew Advisors Inc bought a new stake in Pfizer in the 1st quarter worth approximately $102,000. Earnest Partners LLC bought a new stake in Pfizer in the 4th quarter worth approximately $105,000. Woodard & Co. Asset Management Group Inc. ADV bought a new stake in Pfizer in the 4th quarter worth approximately $118,000. Fort L.P. bought a new stake in shares of Pfizer during the 2nd quarter valued at $121,000. Finally, W.G. Shaheen & Associates DBA Whitney & Co bought a new stake in shares of Pfizer during the 1st quarter valued at $132,000. 68.91% of the stock is owned by institutional investors and hedge funds.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Further Reading: What is a Leveraged Buyout (LBO)?

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply